Home›Trial›NCT03428646
🔬NCT03428646ACTIVE NOT RECRUITING

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

Study Summary

A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)

Conditions
Dermatitis, Atopic
Interventions / Drugs
Dupilumab
View on ClinicalTrials.gov ↗
Sponsor
REGN
Regeneron Pharmaceuticals
Antibody Therapeutics
F34/100
Study Details
Enrollment858 participants
Primary Completion—
Lead SponsorRegeneron Pharmaceuticals
Data Retrieved2026-04-11 02:55:54.866387+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.